Radioactive Drug Research Committee
| Membership Category | Department | Terms expire August 31, 2013: |
|---|---|---|
| Eng, Tony | Radiation Oncology | Radiation Oncology |
| ** Glickman, Randolph | Radiological Sciences | Ophthalmology |
| Gutierrez, Alonso N. | Radiological Sciences | Radiation Oncology |
| * Metter, Darlene F. | Physician/Nuclear Medicine | Radiology |
Terms expire August 31, 2014: | ||
| Furmaga, Wieslaw | Clinical Pathology | Pathology |
| Jerabek, Paul | Positron Emitting Tracers | Research Imaging Center |
| Thomas, John | Radiopharmacist | Radiopharmacist |
| Tripathy, Devjit | Endocrinology | Medicine/Diabetes |
Ex Officio (voting) | ||
| Duffy, Daniel | VA Radiation Safety Rep | Radiology |
| Watson, Jennifer A. | Radiation Safety Officer | Environmental Health & Safety |
| Weiss, David | Dean | Graduate School |
CHARGE:
To serve in an advisory and consultative capacity to the President and the Executive Vice President for Facilities Planning and Operations. To review all research involving the use of radioactive drugs and/or agents with human subjects conducted at or by employees of The University of Texas Health Science Center at San Antonio; the Audie L. Murphy Memorial Veterans Hospital; and the University Hospital System. In accordance with the Food and Drug Administration (21 CFR, Part 361.1) regulations, the Radioactive Drug Research Committee (RDRC) ensures that the use of such drugs is in compliance with these regulations.
If the drug is an Investigational New Drug (IND) with the FDA, it will not be reviewed by the committee. If the drug is a New Drug Approval (NDA) with the FDA, it will not be reviewed by the RDRC.
Term of membership: Two years
Additional information: Committee meets quarterly. Workload of the committee requires knowledge of or interest in learning FDA regulations for radioactive drug development, testing, and approval. Experience with the legal and safe use of such drugs for clinical and research purposes is highly desirable.
* Chair
** Vice Chair